Stocks Health care XFOR
NASDAQ · Health careX4 Pharmaceuticals, Inc (XFOR)
X4 Pharmaceuticals, Inc brought in $17M of revenue over the twelve months to September 30, 2026, down 50.1% from a year earlier. It posted a net loss of $80.5M. In fiscal 2025 capital spending exceeded operating cash flow by $85.6M. At September 30, 2026 it held $185.8M in cash against $75M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about X4 Pharmaceuticals, Inc
- Net worth
- X4 Pharmaceuticals, Inc has a market value (market cap) of $330.2M at the latest share price, and shareholders' equity of $138.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $35.1M (+1,250.5% year on year), with a net loss of $79.2M. Over the 12 months to September 30, 2026: revenue $17M, net loss $80.5M.
- Cash flow
- In fiscal 2025 operations used $85.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- X4 Pharmaceuticals, Inc's next report is expected around March 16, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What X4 Pharmaceuticals, Inc does
X4 Pharmaceuticals, Inc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker XFOR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $35.1M | -$79.2M | -$1.87 | -$85.6M |
| 2024 | $2.6M | -$37.5M | -$5.59 | -$131.2M |
| 2023 | $0 | -$101.2M | -$17.07 | -$96.6M |
| 2022 | $0 | -$93.9M | -$45.52 | -$77.2M |
| 2021 | $0 | -$88.7M | -$119.49 | -$71.5M |
| 2020 | $3M | -$62.1M | -$92.54 | -$60.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where XFOR ranks in Health care
Latest SEC filings
What X4 Pharmaceuticals, Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 63% to $2.9M versus the same quarter last year; diluted EPS -$0.16 versus -$0.69.
- October 29, 2026Other event 8-K
- October 8, 2026Material agreement8-KX4 Pharmaceuticals entered into a senior secured term loan facility of up to $150.0 million with K2 HealthVentures and retired its previous debt.
- October 7, 2026Passive stake changed SCHEDULE 13G/A
- September 21, 2026Passive stake (5% or more) SCHEDULE 13G
- September 9, 2026Other event 8-K
- September 8, 2026Other event 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 346% to $8.8M versus the same quarter last year; diluted EPS -$0.13 versus -$3.47.
Insider trades
What the people running X4 Pharmaceuticals, Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $11.9K and sold $33.7K worth of shares in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 16, 2026 | Craig Adam RExecutive Chairman, Director | Bought | 4,600 | $11.9K |
| October 1, 2026 | Kirske DavidChief Financial Officer | Sold | 11,767 | $33.7K |
| August 12, 2026 | Craig Adam RExecutive Chairman, Director | Sold | 47,436 | $210.8K |
| August 12, 2026 | Volpone JohnPresident | Sold | 24,576 | $109.2K |
| June 30, 2026 | Kirske DavidChief Financial Officer | Sold | 8,543 | $36.4K |
| May 12, 2026 | Kirske DavidChief Financial Officer | Sold | 16,961 | $72.8K |
Who owns XFOR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Coastlands Capital LP13G, passive with 4 related filers | 9.99% | October 3, 2025 |
| Empery Asset Management, LP13G, passive with 1 related filers | 9.99% | January 15, 2026 |
| Fmr LLC13G, passive with 1 related filers | 9.7% | February 5, 2026 |
| Deep Track Capital, LP13G, passive with 3 related filers | 8.33% | August 14, 2026 |
| Perceptive Advisors LLC13G, passive with 2 related filers | 8.1% | August 14, 2026 |
| BCLS II Equity Opportunities, LP13G, passive with 5 related filers | 7.43% | February 17, 2026 |
| Saturn V Capital Management LP13G, passive with 1 related filers | 7.36% | February 17, 2026 |
| Growth Equity Opportunities 18 VGE, LLC13D, may seek influence with 11 related filers | 6.2% | October 29, 2025 |
| Trails Edge Capital Partners, LP13G, passive with 2 related filers | 5.8% | February 17, 2026 |
| Venrock Healthcare Capital Partners III, L.P.13G, passive with 6 related filers | 5.6% | September 21, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 88 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Morgan Stanley | 9,461,279 | -5,713 |
| Fmr LLC | 8,321,657 | +218,257 |
| Bain Capital Life Sciences Investors, LLC | 7,967,454 | 0 |
| Perceptive Advisors LLC | 7,933,491 | +1,195,843 |
| Kalehua Capital Management LLC | 7,445,680 | 0 |
| Saturn V Capital Management LP | 6,973,343 | +516,697 |
| Empery Asset Management, LP | 6,930,591 | -2,013,527 |
| Deep Track Capital, LP | 5,878,757 | -460,778 |
| BlackRock, Inc. | 5,554,906 | +4,343,112 |
| Nantahala Capital Management, LLC | 4,898,936 | +2,449,468 |
| Vanguard Capital Management LLC | 3,715,859 | +218,247 |
| Rosalind Advisors, Inc. | 3,214,766 | 0 |
| Braidwell LP | 2,922,754 | -350,200 |
| Blackstone Inc. | 2,681,922 | 0 |
| Trails Edge Capital Partners, LP | 2,571,478 | 0 |
| Bvf Inc | 2,233,742 | 0 |
| Geode Capital Management, LLC | 2,098,047 | +1,158,321 |
| Venrock Adviser, LLC | 1,934,253 | +1,603,728 |
| Samsara Biocapital, LLC | 1,395,587 | -436,979 |
| State Street Corp | 1,296,017 | +892,483 |
Insiders
3 insiders reported holding 754,539 shares in total, about $2.5M at the last price.
| Holder | Shares |
|---|---|
| Craig Adam RExecutive Chairman, Director | 333,251 |
| Volpone JohnPresident | 265,305 |
| Kirske DavidChief Financial Officer | 155,983 |
Questions about XFOR
What does X4 Pharmaceuticals, Inc do?
X4 Pharmaceuticals, Inc is a company in the Health care sector, listed on NASDAQ as XFOR. Its shares trade on NASDAQ under the ticker XFOR.
What is X4 Pharmaceuticals, Inc's net worth?
X4 Pharmaceuticals, Inc has a market value (market cap) of $330.2M at the latest share price, and shareholders' equity of $138.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is X4 Pharmaceuticals, Inc profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $80.5M on revenue of $17M.
How much revenue does X4 Pharmaceuticals, Inc make?
Over the twelve months to September 30, 2026 X4 Pharmaceuticals, Inc reported revenue of $17M. That is 50.1% less than a year earlier.
When did X4 Pharmaceuticals, Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026.
When is X4 Pharmaceuticals, Inc's next earnings report?
X4 Pharmaceuticals, Inc's next report is expected around March 16, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare XFOR with
Follow XFOR
Get an email when X4 Pharmaceuticals, Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values X4 Pharmaceuticals, Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.